XENOVIEW™ (xenon Xe 129 hyperpolarized)

About Polarean Imaging

Polarean Imaging is a revenue-generating, commercial-stage company pioneering hyperpolarized xenon-129 MRI for functional lung imaging. Its core achievement is the FDA approval in December 2022 of XENOVIEW™, the first and only hyperpolarized MRI contrast agent approved in the United States. The technology addresses significant limitations in current lung imaging by providing quantitative, regional lung function data without ionizing radiation. Polarean aims to serve the vast unmet need in chronic respiratory diseases, targeting a global patient population exceeding 500 million.

Therapeutic Areas